Abstract
The compound 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane, best known by its trivial name o,p’-DDD, has been assigned the generic name Mitotane and is available in the United State under the trade name Lysodren.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abelson, D., Bulaschenko, H., Trommer, P. R., Valdes-Dapena, A.: Malignant interstitial-cell tumor of the testis treated with o,p’-DDD. Metabolism 15, 242–256 (1966).
Azarnoff, D. L., Grady, H. J., Svoboda, D. J.: The effect of DDD on barbiturate and steroid induced hypnosis in the dog and rat. Biochem. Pharmacol. 15, 1985–1993 (1966).
Bergenstal, D. M., Hertz, R., Lipsett, M. B., Moy, R. H.: Chemotherapy of adrenocortical cancer with o,p’-DDD. Ann. int. Med. 53, 672–682 (1960).
Bledsoe, T., Island, D. P., Key, R. L., Liddle, G. W.: An effect of o,p’-DDD on the extra adrenal metabolism of Cortisol in man. J. clin. Endocrinol. 24, 1303–1311 (1964).
Brown, J. H. U., Preedy, J. R. K., Brown, C. H., Hallman, B. L.: Action of an adrenocorticolytic drug in man. Lancet I, 1208–1209 (1959).
Burstein, S., Klaiber, E. L.: Phenobarbital-induced increase in 6β-hydroxycortisol excretion: clue to its significance in human urine. J. clin. Endocrinol. 25, 293–296 (1965).
Cazorla,A., Moncloa, F.: Action of l,l,dichloro-2-p-chlorophenyl-ethane on dog adrenal cortex. Science 136, 47 (1962).
Conney, A. H., Welch, R. W., Kttntzman, R.: Effects of pesticide on drug and steroid metabolism. Clin. Pharmacol. Ther. 8, 2–10 (1967).
Cope, C. L.: The case of the persistent pituitary. Brit. med. J. 2, 557–560 (1969).
Cueto, C., Brown, J. H. A.: Biological studies on an adrenocorticolytic agent and the isolation of the active components. Endocrinology 62, 334–339 (1958).
Danowski, T. S., Sarver, M. E., Moses, C., Bonessi, J. V.: o,p’-DDD therapy in Cushing’s syndrome and in obesity with cushingoid changes. Amer. J. Med. 87, 235–250 (1964).
Datta, P. R.: In vivo detoxification of p,p’-DDT via pp’-DDE to ,p p’-DDA in rats. Indust. Med. 39, 190–194 (1970).
Datta, P. R., Nelson, M. J.: pp’-DDT detoxication by isolated perfused rat liver and kidney. Indust. Med. 89, 195–198 (1970).
Digiulio, W., Beierwaltes, W. H.: Tissue localization studies of a DDD analog. J. nucl. Med. 9, 634–637 (1968).
Finnegan, J. K., Haag, H. B., Larson, P. S.: Tissue distribution and elimination of DDD and DDT following oral administration to dogs and rats. Proc. Soc. exp. Biol. (N. Y.) 72, 357–360 (1949).
Fisher, D. A., Panos, T. C., Melby, J. C.: Therapy of adrenocortical cancer with o,p’-DDD in two children. J. clin. Endocrinol. 23, 218–221 (1963).
Fukushima, D. K., Bradlow, H. L., Hellman,L.: Effects of o,p’ DDD on Cortisol and 6-beta- hydroxycortisol secretion and metabolism in man. J. clin. Endocrinol. 32, 192–200 (1971).
Grady, H. J., Azarnoff, D. L., Creager, R., Huffman, D. H., Nichols, J.: Specificity of enzyme inhibition by DDD. Proc. Soc. exp. Biol. (N.Y.) 119, 238–241 (1965).
Greene, F. E., Stripp, B., Gillette, J. R.: The effect of carbon tetrachloride on heme components and ethylmorphine metabolism in rat liver microsomes. Biochem. Pharmacol. 18, 1631–1533 (1969).
Hart, M. M., Reagan, R. L., Adamson, R. H.: The effect of isomers of DDD on the ACTH induced steroid output, histology and ultrastructure of the dog adrenal cortex. Toxicol. Appl. Pharmacol. 24, 101–113 (1973).
Hart, M. M., Straw, J. A.: Effect of l-(o-chlorophenyl)-l-(p-chlorophenyl)-2,2-dichloroethane on adrenocorticotropic hormone-induced steroidogenesis in various preparations in vitro of dog adrenal cortex. Biochem. Pharmacol. 20, 1679–1688 (1971a).
Hart, M. M., Straw, J. A.: Effect of l-(o-chlorophenyl)-l-(p-chlorophenyl)-2,2-dichloroethane in vivo on baseline and adrenocorticotropic hormone-induced steroid production in dog adrenal slices. Biochem. Pharmacol. 20, 1689–1691 (1971b).
Hart, M. M., Straw, J. A.: Studies on the site of action of o,p’-DDD in the dog adrenal cortex. I. Inhibition of ACTH-mediated pregnenolone synthesis. Steroids 17, 559–574 (1971c).
Hart, M. M., Straw, J. A.: Effects of l-(o-chlorophenyl)-l-(p-chlorophenyl)-2,2-dichloroethane and puromycin on adrenocorticotropic hormone-induced steroidogenesis and on amino acid incorporation in slices of dog adrenal cortex. Biochem. Pharmacol. 20, 257–263 (1971 d).
Hart, M. M., Swackhamer, E. S., Straw, J. A.: Studies on the site of action of o,p’-DDD in the dog adrenal cortex. II. TPNH and corticosteroid precursor-stimulation of o,p’-DDD inhibited steroidogenesis. Steroids 17, 575–586 (1971).
Hutter, A. M., Kayhoe, D. E.: Adrenal cortical carcinoma — Clinical features of 138 patients. Amer. J. Med. 41, 572–580 (1966a).
Hutter, A. M., Kayhoe, D. E.: Adrenal cortical carcinoma — Results of treatment with o,p’- DDD in 138 patients. Amer. J. Med. 41, 581–592 (1966b).
Kaminsky, N., Luse, S., Hartroft, P.: Ultrastructure of adrenal cortex of the dog during treatment with DDD. J. nat. Cancer Inst. 29, 127–159 (1962).
Kupfer, D., Peets, L.: The effects of o,p’-DDD on Cortisol and hexobarbital metabolism. Biochem. Pharmacol. 15, 573–581 (1966).
Lipsett, M. B., Kirschner, M. A., Wilson, H., Bardin, C. W.: Malignant lipid cell tumor of the ovary. Clinical, biochemical and etiologic considerations. J. clin. Endocrinol. 30, 336–344 (1970).
Lubitz, J.A., Freeman, L., Okun, R.: Mitotane use in inoperable adrenal cortical carcinoma. J. Amer. med. Ass. 233, 1109–1112 (1973).
Marshall, J. A., Tompkins, L.S.: Effect of o,p’-DDD and similar compounds on thyroxine binding globulin. J. clin. Endocrinol. 24, 386–392 (1968).
Martz, F., Straw, J. A.: Effects of Mitotane (o,p’-DDD) on hepatic drug metabolism in dogs. Fed. Proc. 81, 581 (1972).
Martz, F., Straw, J. A.: Mitotane decreases adrenal cortical heme and P450. F.d. Proc. 32 (3), 734 (1973).
Molnar, G. D., Mattox, V. R., Bahn, R. C.: Clinical and therapeutic observations in adrenal cancer. A report on 7 patients treated with o,p’-DDD. Cancer 16, 259–268 (1963).
Moy, R. H.: Studies of the pharmacology of o,p’-DDD in man. J. Lab. clin. Med. 58, 296–304 (1961).
Nelson, A. A., Woodward, G.: Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(para-chlorophenyl)-l,l-dicMoroethane (DDD or TDE). Arch. Path. 48, 387–394 (1949).
Nichols, J.: Studies on an adrenal cortical inhibitor. In: Moon, H. D. (Ed.): The adrenal cortex. Int. Acad, of Path. Monograph. New York: Harper and Brothers 1961.
Nichols, J., Green, H. D.: Effect of DDD treatment on metabolic response of dogs to ACTH injection. Amer. J. Physiol. 176, 374–376 (1954).
Nichols, J., Hennigar, G.: Studies on DDD, 2,2-bis-(parachlorophenyl)-1,1 -dichloroethane. Exp. Med. Surg. 15, 310–316 (1957).
Nichols, J., Prestley, W. F., Nichols, F.: Effects of m,p’-DDD in a case of adrenal corticol carcinoma. Curr. Ther. Res. 3, 266–271 (1961).
Sakauchi, N., Kumaoka, S., Naruke, T., Abe, O., Kusama, M., Takatani, O.: A case of adrenocortical cancer treated with o,p’-DDD. Endocrinology 16, 287–290 (1969).
Southren, A. L., Tochimoto, S., Strom, L., Ratuschni, A., Ross, R., Gordon, G.: Remission in Cushing’s syndrome with o,p’-DDD. J. clin. Endocrinol. 26, 268–278 (1966).
Southren, A. L., Weisenfeld, S., Laufer, A., Goldner, M.G.: Effect of o,p ’-DDD in a patient with Cushing’s syndrome. J. clin. Endocrinol. 21, 201–208 (1961).
Straw, J. A., Waters, I. W., Fregly, M. J.: Effect of o,p’-DDD on hepatic metabolism of pentobarbital in rats. Proc. Soc. exp. Biol. 118, 391–394 (1965).
Tamoney, H. J., Jr., Noriega,A.: Malignant interstitial cell tumor of the testis. Cancer 24, 547–551 (1969).
Temple, T. E., Jones, D. J., Liddle, G. W., Dexter, R. N.: Treatment of Cushing’s disease. Correction of hypercortisolism by o,p’-DDD without induction of aldosterone deficiency. N. Engl. J. Med. 281, 801–805 (1969).
Wallace, E. Z., Silverstein, J. N., Villadolid, L. S., Weisenfeld, S.: Cushing’s syndrome due to adrenocortical hyperplasia. N. Engl. J. Med. 265, 1088–1093 (1961).
Wedemeyer, G.: Dechlorination of l,l,l-trichloro-2,2-bis(p-chlorophenyl)ethane by Aerobacter aerogenes. Appl. Microbiol. 15, 569–574 (1967).
Weisenpeld, S., Hecht, A., Leichter, D., Goldner, M.: o,p’-DDD in the treatment of advanced mammary carcinoma. Cancer 17, 1258–1266 (1964).
Zimmerman, B., Blooh, H. L., Williams, W. L., Hitchcock, C. R., Hoelscher,B.: The effects of DDD [l,l-dichloro-2,2-bis(p-chlorophenyl)ethane] on the human adrenal. Cancer 9, 940–948 (1956).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1975 springer-Verlag Berlin-Heidelberg
About this chapter
Cite this chapter
Straw, J.A., Hart, M.M. (1975). 1-(o-Chlorophenyl)-1-(p-Chlorophenyl)-2,2-Dichloroethane (o,p’-DDD), an Adrenocorticolytic Agent. In: Sartorelli, A.C., Johns, D.G. (eds) Antineoplastic and Immunosuppressive Agents. Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology, vol 38 / 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-65806-8_45
Download citation
DOI: https://doi.org/10.1007/978-3-642-65806-8_45
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-65808-2
Online ISBN: 978-3-642-65806-8
eBook Packages: Springer Book Archive